Curi RMB Capital’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.2M | Buy |
119,992
+7,586
| +7% | +$1.43M | 0.31% | 92 |
|
|
2026
Q1 | $22.2M | Buy |
112,406
+58,115
| +107% | +$11.2M | 0.39% | 66 |
|
|
2025
Q4 | $9.98M | Buy |
54,291
+14,322
| +36% | +$2.51M | 0.17% | 142 |
|
|
2025
Q3 | $6.13M | Sell |
39,969
-15,548
| -28% | -$2.35M | 0.11% | 195 |
|
|
2025
Q2 | $7.76M | Buy |
55,517
+11,668
| +27% | +$1.64M | 0.15% | 173 |
|
|
2025
Q1 | $6.45M | Buy |
+43,849
| New | +$6.34M | 0.16% | 168 |
|
|
2024
Q2 | – | Sell |
-1,923
| Closed | -$261K | – | 529 |
|
|
2024
Q1 | $261K | Sell |
1,923
-2,573
| -57% | -$341K | 0.01% | 512 |
|
|
2023
Q4 | $606K | Buy |
4,496
+45
| +1% | +$5.85K | 0.02% | 366 |
|
|
2023
Q3 | $603K | Buy |
4,451
+244
| +6% | +$33.3K | 0.02% | 350 |
|
|
2023
Q2 | $602K | Sell |
4,207
-277
| -6% | -$40.8K | 0.02% | 349 |
|
|
2023
Q1 | $622K | Sell |
4,484
-1,177
| -21% | -$158K | 0.02% | 342 |
|
|
2022
Q4 | $768K | Sell |
5,661
-594
| -9% | -$74.5K | 0.03% | 312 |
|
|
2022
Q3 | $686K | Buy |
6,255
+289
| +5% | +$36.7K | 0.03% | 323 |
|
|
2022
Q2 | $788K | Buy |
5,966
+1,486
| +33% | +$195K | 0.03% | 303 |
|
|
2022
Q1 | $594K | Buy |
4,480
+343
| +8% | +$41.1K | 0.02% | 316 |
|
|
2021
Q4 | $482K | Buy |
4,137
+1,364
| +49% | +$160K | 0.01% | 358 |
|
|
2021
Q3 | $333K | Buy |
2,773
+380
| +16% | +$44.2K | 0.01% | 383 |
|
|
2021
Q2 | $287K | Hold |
2,393
| – | – | 0.01% | 415 |
|
|
2021
Q1 | $238K | Sell |
2,393
-21
| -0.9% | -$2.11K | 0.01% | 419 |
|
|
2020
Q4 | $241K | Sell |
2,414
-343
| -12% | -$36.3K | 0.01% | 531 |
|
|
2020
Q3 | $302K | Hold |
2,757
| – | – | 0.01% | 494 |
|
|
2020
Q2 | $292K | Sell |
2,757
-36
| -1% | -$3.72K | 0.01% | 482 |
|
|
2020
Q1 | $250K | Sell |
2,793
-206
| -7% | -$19.4K | 0.01% | 520 |
|
|
2019
Q4 | $299K | Sell |
2,999
-20
| -0.7% | -$1.88K | 0.01% | 551 |
|
|
2019
Q3 | $269K | Hold |
3,019
| – | – | 0.01% | 601 |
|
|
2019
Q2 | $249K | Buy |
3,019
+85
| +3% | +$6.67K | 0.01% | 659 |
|
|
2019
Q1 | $237K | Buy |
+2,934
| New | +$231K | 0.01% | 711 |
|
|
2014
Q3 | – | Sell |
-2,931
| Closed | -$218K | – | 442 |
|
|
2014
Q2 | $218K | Sell |
2,931
-1,028
| -26% | -$74.3K | 0.01% | 396 |
|
|
2014
Q1 | $257K | Sell |
3,959
-1,257
| -24% | -$81.2K | 0.02% | 323 |
|
|
2013
Q4 | $309K | Sell |
5,216
-805
| -13% | -$43.7K | 0.02% | 286 |
|
|
2013
Q3 | $312K | Sell |
6,021
-1,994
| -25% | -$100K | 0.02% | 291 |
|
|
2013
Q2 | $380K | Buy |
+8,015
| New | +$408K | 0.03% | 264 |
|
Other funds holding AZN
EP
IA
Curi RMB Capital's AZN Position: Q2 2026 in Review
Curi RMB Capital increased its AstraZeneca (AZN) stake by 6.7% in Q2 2026, buying an estimated $1.43M and bringing the position to 119,992 shares worth $20.2M. The position accounts for 0.31% of the portfolio, ranked #92.
Curi RMB Capital first reported a position in AZN in Q2 2013 and has held it in 32 quarters since. The position peaked at $22.2M in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Curi RMB Capital held 119,992 shares of AstraZeneca worth $20.2M as of Q2 2026.
- Curi RMB Capital bought 7,586 AstraZeneca shares in Q2 2026, an estimated $1.43M.
- AstraZeneca made up 0.31% of Curi RMB Capital's portfolio in Q2 2026, its #92 holding.
- Curi RMB Capital first reported a position in AstraZeneca in Q2 2013 and has held it in 32 quarters since.
- Curi RMB Capital's AstraZeneca position peaked at $22.2M in Q1 2026.
- 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.